Description:
This multicenter, randomized, open-label, parallel-group study will evaluate the efficacy and
safety of subcutaneously administered rituximab in comparison with observation only as
maintenance therapy in participants with relapsed or refractory indolent Non-Hodgkin's
lymphoma (NHL). All participants will receive induction therapy with rituximab (375
milligrams per square meter [mg/m^2] intravenously [IV] in Cycle 1, then 1400 mg subcutaneous
[SC] every 3-4 weeks) plus standard chemotherapy for 6-8 months; followed by 24 months of
maintenance I period with rituximab (1400 mg SC every 8 weeks). Participants completing
therapy and showing partial or complete response will be randomized to receive either
rituximab (1400 mg SC every 8 weeks) or observation with no treatment during maintenance II
period and will be followed for at least 15 months. Anticipated time on study treatment is
until disease progression, unacceptable toxicity or end of study, whichever occurs first.
Title
- Brief Title: A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
- Official Title: A Randomized Study Comparing Maintenance Therapy With Subcutaneous Rituximab Continued Until Progression With Observation Only in Patients With Relapsed or Refractory, Indolent Non-Hodgkin's Lymphoma Who Completed and Responded to Rituximab-based Immunochemotherapy Induction and Initial 2-year Rituximab Maintenance Therapy Administered Subcutaneously
Clinical Trial IDs
- ORG STUDY ID:
MO25455
- SECONDARY ID:
2010-023407-95
- NCT ID:
NCT01461928
Conditions
Interventions
| Drug | Synonyms | Arms |
|---|
| Chemotherapy (Induction Period) | | Maintenance II Period Observation Only |
| Rituximab | Rituxan, MabThera, RO0452294 | Maintenance II Period Observation Only |
Purpose
This multicenter, randomized, open-label, parallel-group study will evaluate the efficacy and
safety of subcutaneously administered rituximab in comparison with observation only as
maintenance therapy in participants with relapsed or refractory indolent Non-Hodgkin's
lymphoma (NHL). All participants will receive induction therapy with rituximab (375
milligrams per square meter [mg/m^2] intravenously [IV] in Cycle 1, then 1400 mg subcutaneous
[SC] every 3-4 weeks) plus standard chemotherapy for 6-8 months; followed by 24 months of
maintenance I period with rituximab (1400 mg SC every 8 weeks). Participants completing
therapy and showing partial or complete response will be randomized to receive either
rituximab (1400 mg SC every 8 weeks) or observation with no treatment during maintenance II
period and will be followed for at least 15 months. Anticipated time on study treatment is
until disease progression, unacceptable toxicity or end of study, whichever occurs first.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Maintenance II Period Observation Only | Other | Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); no treatment in Maintenance II period until disease progression or end of study, whichever occurs first. | - Chemotherapy (Induction Period)
- Rituximab
|
| Maintenance II Period Rituximab | Experimental | Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); 1400 mg rituximab SC every 8 weeks until disease progression or end of study, whichever occurs first (Maintenance II period). | - Chemotherapy (Induction Period)
- Rituximab
|
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed Cluster of Differentiation 20-positive (CD20+) follicular NHL
Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström's macroglobulinemia or
lymphoplasmacytic lymphoma, marginal zone lymphoma) according to World Health
Organization (WHO) classification system
- Participants must have received and must have relapsed or been refractory to, one or
more lines of adequate therapy prior to enrollment, including at least one line
consisting of immunotherapy and/or chemotherapy and/or radiotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
(<=) 2
Exclusion Criteria:
- Transformation to high-grade lymphoma
- Aggressive lymphoma (for example, mantle cell lymphoma [MCL])
- Presence or history of central nervous system (CNS) lymphomatous disease
- Other malignancy within 5 years prior to enrollment, except for curatively treated
carcinoma in situ of the cervix, squamous cell carcinoma of the skin or basal cell
skin cancer, or cervical carcinoma Stage 1B or less, breast cancer in situ or
localized prostate cancer Stage T1c if treated with curative intent and relapse- and
metastasis-free for at least 2 years prior to enrollment
- Inadequate hematological, hepatic or renal function
- Known human immunodeficiency virus (HIV) infection
- Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic
infections, active hepatitis B or C)
- Pregnant or breastfeeding women
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia |
| Time Frame: | From randomization (Maintenance II) up to disease progression or death, whichever occurs first (up to approximately 24 months) |
| Safety Issue: | |
| Description: | Progression free survival from randomization (PFSrand) is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. One participant died in Induction before randomization and one participant died in Maintenance II Observation arm due to an SAE and were not considered in the analysis as no death page was completed. The Observation arm did not include one participant with AE outcome of death reported retrospectively 2 months after discontinuation from study (censored as having no event on Day 456 post-randomization). |
Secondary Outcome Measures
| Measure: | Number of Participants With Adverse Events (AEs), Serious AEs, and Infusion/Administration-related Reactions (IRRs/ARRs) |
| Time Frame: | From day of first rituximab induction dose up to day of disease progression, or discontinuation of treatment for any reason (up to approximately 87 months) |
| Safety Issue: | |
| Description: | An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Not all AEs were followed up for the randomized Observation arm. Only Serious AEs and AE grade 3-5 (obtained retrospectively) were collected for this arm. Therefore arms are not comparable overall. |
| Measure: | Event-free Survival (Time to Treatment Failure) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia |
| Time Frame: | From day of first rituximab induction dose up to day of any treatment failure, including disease progression, or discontinuation of treatment for any reason (up to approximately 87 months) |
| Safety Issue: | |
| Description: | Event-Free Survival was measured from the day of first rituximab Induction dose through Maintenance I and Maintenance II rituximab arm until the date of any treatment failure, including disease progression, or discontinuation of treatment for any reason (e.g. disease progression, toxicity, patient preference, initiation of new anti-lymphoma treatment, or death). Treatment discontinuation was considered as an event and was not applicable to the randomized observation arm. |
| Measure: | Time to Next Lymphoma Treatment (TNLT) |
| Time Frame: | From day of first rituximab induction dose up to any new lymphoma treatment (up to approximately 87 months) |
| Safety Issue: | |
| Description: | Time to next lymphoma treatment (TNLT) is defined as the time from date of first rituximab induction dose to the date date of first documented intake of any new antilymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc.). |
| Measure: | Overall Survival |
| Time Frame: | From day of first rituximab induction dose up to death (up to approximately 87 months) |
| Safety Issue: | |
| Description: | Overall survival from first induction treatment (OSRegist) is defined as the time from date of first rituximab induction dose to the date of death, irrespective of cause. One participant died in Induction before randomization and one participant died in Maintenance II Observation arm due to an SAE and were not considered in the analysis as no death page was completed. |
| Measure: | Maintenance II: Overall Survival |
| Time Frame: | From randomization (Maintenance II) up to death (up to approximately 24 months) |
| Safety Issue: | |
| Description: | Overall survival from randomization (OSrand) is defined as the time from date of randomization to the date of death, irrespective of cause. |
| Measure: | Percentage of Participants With Partial or Complete Tumor Response (PR/CR) Assessment at End of Induction Using 1999 International Working Group Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia |
| Time Frame: | From day of first rituximab induction dose up to end of induction period (up to approximately 8 months) |
| Safety Issue: | |
| Description: | Overall response rate is defined as the proportion of responders at the end of the Induction period. A responder is defined as a participant experiencing either CR or PR tumor response according to the Cheson response criteria for indolent lymphoma or the recommendations for Waldenström's macroglobulinemia. |
| Measure: | Maintenance I: Percentage of Participants With Conversion of PR to CR Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia |
| Time Frame: | From day of first rituximab induction dose up to end of Maintenance I period (up to approximately 32 months) |
| Safety Issue: | |
| Description: | |
| Measure: | Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia |
| Time Frame: | From day of first rituximab induction dose up to disease progression or death, whichever occurs first (up to approximately 87 months) |
| Safety Issue: | |
| Description: | Progression free survival from first induction treatment (PFSregist) is defined as the time from date of first rituximab induction dose to the date of first documented disease progression or death by any cause, whichever occurs first. |
Details
| Phase: | Phase 3 |
| Primary Purpose: | Interventional |
| Overall Status: | Completed |
| Lead Sponsor: | Hoffmann-La Roche |
Last Updated
August 6, 2019
